Paul Rothman appointed to second term as leader of Johns Hopkins Medicine

With enthusiastic support from university and Johns Hopkins Medicine leaders and colleagues, Paul Rothman has been appointed to a second term as CEO of Johns Hopkins Medicine and dean of Johns Hopkins University's School of Medicine. He began a new six-year term this summer.

Image caption: Paul Rothman

In a message today to faculty, staff, and students, Johns Hopkins University President Ronald J. Daniels praised Rothman for his "exceptional leadership, advancing our clinical, research, and educational missions.

"Conversations with students, faculty, staff, and administrators throughout Johns Hopkins Medicine," he added, "confirmed our strong belief that Paul possesses and articulates a sharp and nuanced understanding of this institution's role in delivering the highest quality care to patients at home and abroad, producing new discoveries and embracing research agendas that are critical to the health of world, and educating the next generation of premier clinicians and scientists."

Daniels commended Rothman's commitment to research and discovery amid constrained funding, as well as his support in partnership with fellow deans and directors for early- and mid-career scientists.

Rothman joined Johns Hopkins University in 2012 as the second CEO of Johns Hopkins Medicine and the 14th dean of the School of Medicine.

As dean and CEO, Daniels said, Rothman has:

• Recruited and appointed leaders across the School of Medicine, in the dean's office, and across the health system

• Initiated the development and implementation of Johns Hopkins Medicine's first enterprise-wide strategic plan, providing guidance on the shared principles and aspirations that help align and integrate the enterprise

• Worked closely with Ronald R. Peterson, president of the Johns Hopkins Health System, and other key colleagues to implement key operational changes, including the successful roll out of the electronic medical records system EPIC, and the smooth transition to the new clinical facilities in the Charlotte R. Bloomberg Children's Center and the Sheik Zayed Tower

• Made substantial investments in precision medicine while simultaneously developing Centers of Excellence that will apply these principles to medical practice, advancing Johns Hopkins Medicine's potential to fundamentally alter patient outcomes

• Worked to drive the Bloomberg Distinguished Professorship program, recruiting a cadre of exceptional interdisciplinary researchers and clinicians that is helping to sustain research excellence

• Supported the 2015 launch of Johns Hopkins Technology Ventures to aid faculty, students, and staff in translating their discoveries into market-ready treatments

  "Time and again during the reappointment evaluation process, colleagues from across our institution described Paul as the consummate clinician-scientist, a leader who has the skill and vision to see and advance priorities in both research and clinical practice without losing sight of the joy of medicine," Daniels said. "He is an exemplary partner and colleague, and we are delighted that our health system, our university, and our School of Medicine will benefit from his continued leadership over the next six years."